Serum S-100B adds incremental value for the prediction of symptomatic intracranial hemorrhage and brain edema after acute ischemic stroke
Tim Honegger,Juliane Schweizer,Antonela Bicvic,Laura P Westphal,Valerie Schütz,Corinne Inauen,Thomas Pokorny,Katja Bracher,Marcel Arnold,Urs Fischer,Leo H Bonati,Gian Marco De Marchis,Krassen Nedeltchev,Timo Kahles,Carlo Cereda,Georg Kägi,Joan Montaner,Alejandro Bustamante,Elena Palà,George Ntaios,Christian Foerch,Andreas Luft,Katharina Spanaus,Lanja Saleh,Arnold von Eckardstein,Markus Arnold,Mira Katan
DOI: https://doi.org/10.1177/23969873221145391
IF: 6.1
2022-12-22
European Stroke Journal
Abstract:European Stroke Journal, Ahead of Print. Background:Early identification of patients developing symptomatic intracranial hemorrhage and symptomatic brain edema after acute ischemic stroke is essential for clinical decision-making. Astroglial protein S-100B is a marker of blood-brain barrier disruption, which plays an important role in the formation of intracranial hemorrhage and brain edema. In this study, we assessed the prognostic value of serum S-100B for the development of these complications.Methods:Serum S-100B levels were measured within 24 h from symptom onset in 1749 consecutive acute ischemic stroke patients from the prospective, observational, multicenter BIOSIGNAL cohort study (mean age 72.0 years, 58.3% male). To determine symptomatic intracranial hemorrhage or symptomatic brain edema, follow-up neuroimaging was performed in all patients receiving reperfusion therapy or experiencing clinical worsening with an NIHSS increase of ⩾4.Results:Forty six patients (2.6%) developed symptomatic intracranial hemorrhage and 90 patients (5.2%) developed symptomatic brain edema. After adjustment for established risk factors, log10S-100B levels remained independently associated with both symptomatic intracranial hemorrhage (OR 3.41, 95% CI 1.7–6.9, p = 0.001) and symptomatic brain edema (OR 4.08, 95% CI 2.3–7.1, p < 0.001) in multivariable logistic regression models. Adding S-100B to the clinical prediction model increased the AUC from 0.72 to 0.75 (p = 0.001) for symptomatic intracranial hemorrhage and from 0.78 to 0.81 (p < 0.0001) for symptomatic brain edema.Conclusions:Serum S-100B levels measured within 24 h after symptom onset are independently associated with the development of symptomatic intracranial hemorrhage and symptomatic brain edema in acute ischemic stroke patients. Thus, S-100B may be useful for early risk-stratification regarding stroke complications.